hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
== Epidemiology == MG occurs in all ethnic groups and both sexes. It most commonly affects women under 40 and people from 50 to 70 years old of either sex, but it has been known to occur at any age. Younger people rarely have thymoma. Prevalence in the United States is estimated at between 0.5 and 20.4 cases per 100,000, with an estimated 60,000 Americans affected. In the United Kingdom, an estimated 15 cases of MG occur per 100,000 people. The mortality rate of MG is around 5-9%.
==== 100–199 ==== Air Fares (Amendment) Regulations 1993 (S.I. 1993/100) Licensing of Air Carriers (Amendment) Regulations 1993 (S.I. 1993/101) Local Government and Housing Act 1989 (Commencement No. 15) Order 1993 (S.I. 1993/105) Education (School Financial Statements) (Prescribed Particulars etc.) Regulations 1993 (S.I. 1993/113) Teachers' Superannuation (Amendment) Regulations 1993 (S.I. 1993/114) British Railways (Penalty Fares) Act 1989 (Activating No. 8) Order 1993 (S.I. 1993/115) A31 Trunk Road (Ashley Heath Grade Separated Junction) Order 1993 (S.I. 1993/116) Local Government Act 1988 (Defined Activities) (Exemption) (Boothferry Borough Council) Order 1993 (S.I. 1993/117) Act of Sederunt (Fees of Messengers-at-Arms) 1993 (S.I. 1993/118) Value Added Tax (General) (Amendment) Regulations 1993 (S.I. 1993/119) Act of Sederunt (Fees of Sheriff Officers) 1993 (S.I. 1993/120) Testing in Primary Schools (Scotland) Revocation Regulations 1993 (S.I. 1993/121) East Birmingham Hospital National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/122) Teddington Memorial Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/123) Revenue Support Grant (Specified Bodies) (Amendment) Regulations 1993 (S.I. 1993/139) A35 Trunk Road (40 mph Speed Limit) Order 2003 (S.I. 1993/142) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) (No.2) Order 1993 (S.I. 1993/143) Council Tax (Additional Provisions for Discount Disregards) (Amendment) Regulations 1993 (S.I. 1993/149) Council Tax (Exempt Dwellings) (Amendment) Order 1993 (S.I.
=== Heart failure === DCA has been investigated as a treatment for post-ischemic recovery. There is also evidence that DCA improves metabolism by NADH production stimulation, but may lead to a depletion of NADH in normoxia.
=== Non-encoded nucleotides are added to the ends of RNA molecules === Molecular analysis of mRNA molecules showed that, following transcription, mRNAs have non-DNA-encoded nucleotides added to both their 5′ and 3′ ends (guanosine caps and poly-A, respectively). Enzymes were also identified that add and maintain the universal CCA sequence on the 3′ end of tRNA molecules. These events are among the first discovered examples of RNA processing, a complex series of reactions that are needed to convert RNA primary transcripts into biologically active RNA molecules.
In the same month, Sanders gave an interview to Mamdani in which they discussed Sanders's political beginnings and his achievements as a mayor and senator. On September 15, 2025, Sanders said that Israel is committing genocide in Gaza, becoming the first US senator to make such comment. In early February 2026, he criticized the U.S. government's proposed military aid to Israel. In a post on social media, he wrote that the U.S. was planning to send approximately $7 billion in weapons to Israel. Sanders argued that the U.S. should prioritize domestic needs, such as healthcare for all Americans, rather than provide military assistance to Israel. In April 2026, he proposed a resolution to block certain military aid to Israel, which failed. After Trump's speech at the United Nations on September 22, 2026, Sanders said that Trump's threat to "annihilate" Iran was a "war crime" and wrote: "Let's be clear: Trump's war in Iran is illegal and unconstitutional. Congress must end it NOW."
Sources: en.wikipedia.org
== Relationship to docking methods == The field of protein–protein interaction prediction is closely related to the field of protein–protein docking, which attempts to use geometric and steric considerations to fit two proteins of known structure into a bound complex. This is a useful mode of inquiry in cases where both proteins in the pair have known structures and are known (or at least strongly suspected) to interact, but since so many proteins do not have experimentally determined structures, sequence-based interaction prediction methods are especially useful in conjunction with experimental studies of an organism's interactome.
In 1900, at the home of the Carstairs in Idris, there was an argument between the Carstairs siblings regarding the possession of Cortana. Cordelia stated that she wanted to be a merciful hero and Alastair merely said that the sword belonged to him as he was the Carstairs heir. However, Cortana flew back into Cordelia's hand, "choosing its owner." The group goes to Tower Bridge to try to fight and capture the demon, but it breaks free of the Pyxis. During their fight against the Mandikhor, Cordelia is knocked into the Thames, but Lucie summons all the ghosts of London to her aid and they pull Cordelia out of the waters. When the demon departs, it speaks to James and tries to convince him to go to Belial's realm. Christopher has figured out the cure but cannot make it work without an illegal ingredient. James locates where it may be found but before they could retrieve it, Christopher is attacked and poisoned himself. Cordelia's mother reveals that she's pregnant. While receiving treatment in the Silent City, James, Cordelia, and Matthew sneak in and talked with Christopher. Christopher, under the influence of the infection, grabs James's wrist, infecting him, while trying to warn him that he was in danger and all the attacks were about him. Meanwhile, Thomas searches the Chiswick grounds for the root and Lucie wanders off to a shed, where she spies on Grace Blackthorn. She notices Jesse Blackthorn's body, in a glass coffin, where he appears to be asleep. She hears Grace talking about her mother hurting James when suddenly a demon attacks her.
==== Metabolism ==== Mephedrone undergoes extensive metabolism, primarily through the cytochrome P450 2D6 (CYP2D6) enzyme. The main phase I metabolic pathways include N-demethylation, reduction of the ketone moiety, and oxidation of the tolyl group. Key metabolites identified in human plasma and urine include nor-mephedrone, dihydro-mephedrone, hydroxytolyl-mephedrone, and 4-carboxy-mephedrone, with 4-carboxy-mephedrone being the most abundant. Based on the analysis of rat and human urine by gas chromatography and mass spectrometry, mephedrone is thought to be metabolised by three phase 1 pathways. It can be demethylated to the primary amine (producing compounds 2, 3 and 5), the ketone group can be reduced (producing 3), or the tolyl group can be oxidised (producing 6). Both 5 and 6 are thought to be further metabolised by conjugation to the glucuronide and sulfate derivatives. Knowledge of the primary routes of metabolism should allow the intake of mephedrone to be confirmed by drug tests, as well as more accurate determination of the causes of side effects and potential for toxicity.
Combination of TMA-2 with harmaline or ibogaine has been reported to result in long-lasting episodes complicated by severe psychomotor agitation. TMA-2's affinity (Ki) for the serotonin 5-HT2A receptor has been found to be 1,300 nM. Its EC50Tooltip half-maximal effective concentration at the receptor was 190 nM and its EmaxTooltip maximal efficacy was 84%. The drug was also active at the serotonin 5-HT2B receptor and, to a much lesser extent, at the serotonin 5-HT2C receptor. In an earlier study, its affinities (Ki) were 1,650 nM at the serotonin 5-HT2 receptor and 46,400 nM at the serotonin 5-HT1 receptor. TMA-2 is inactive at the monoamine transporters. It was inactive at the mouse trace amine-associated receptor 1 (TAAR1), whereas it bound to the rat TAAR1 with an affinity (Ki) of 3,100 nM and was not assessed at the human TAAR1. In terms of metabolism, TMA-2 is known to be at least partially O-demethylated in animals in vivo. It might produce 2,4,5-trihydroxyamphetamine (THA) as a metabolite. The pharmacokinetics and metabolism of TMA-2 in humans are unknown.
where N0 is the number of atoms of the isotope in the original sample (at time t = 0, when the organism from which the sample was taken died), and N is the number of atoms left after time t. λ is a constant that depends on the particular isotope; for a given isotope it is equal to the reciprocal of the mean-life – i.e. the average or expected time a given atom will survive before undergoing radioactive decay. The mean-life, denoted by τ, of 14C is 8,267 years, so the equation above can be rewritten as:
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.